C urrent immunosuppressive regimens control acute rejection of transplanted organs. 1 However, transplant arteriosclerosis continues to be a primary obstacle to long-term survival of the transplanted heart. Despite a rapidly growing body of data concerning the involved immunological events, the exact pathogenetic mechanisms for this immunologically mediated form of arteriosclerosis remain unclear. Experimental models show that vascular thickening develops in stages. 2, 3 An initial vascular injury is established by an acute alloimmune response involving recipient-derived T cells, B cells, and macrophages and graft endothelial cells. This initial injury is followed by infiltration of activated macrophages and lymphocytes within the vessels and initiation of an inflammatory activation cascade. Finally, this develops into a late stage with neointimal SMC expansion, extracellular matrix formation, and late intimal fibrosis. Understanding key regulators of these arteriosclerotic stages and their precise mode of action may lead to development of more selective interventions.
NO has been implicated as a potential regulator in each of these arteriosclerotic stages. 4 NO is formed from L-arginine by the enzyme NO synthase, which exists in different isoforms. 5 The cytokine-inducible isoform of NO synthase (NOS2 or iNOS) responds to inflammatory stimuli producing large amounts of NO. 6, 7 NO is a pleiotropic signaling molecule involved in numerous processes. 7 Among its effector functions, those pertinent to arteriosclerotic lesion development in transplanted organs could regulate immune cells 8, 9 and/or SMCs. 7 In addition to the well-described role of macrophage-derived NO in antimicrobial processes, NO is a mediator of T-cell responses. 8 Th 1 -differentiated lymphocytes, a T-cell subset associated with an accelerated alloimmune response, 10 have been shown to express high levels of NOS2 comparable to levels produced by macrophages. 11 NO inhibits the expansion of cloned Th 1 but not Th 2 cells, 11 a subset that has been hypothesized to be associated with allograft acceptance. NOS2 deficiency produced by gene targeting results in preferential expansion of Th 1 lymphocytes. 12 Conversely, NO exhibits potential antiproliferative effects in the vasculature, including inhibition of VSMC migration 13 and proliferation. 14, 15 In balloon injury models, treatment with different NO donors reduces neointimal formation, an effect that can be blocked by coadministration of an inhibitor of NOS. 16 -19 Hence, NO generated by NOS2 may play a role in the early immune system-driven and/or later SMC stage of transplant arteriosclerosis. In transplanted organs, NOS2 expression shows an early and persistent upregulation resulting in increased levels of NO. 4, 20, 21 Development of transplant arteriosclerosis is associated with induction of NOS2 expression in many cell types involved in lesion formation, such as macrophages, lymphocytes, VSMCs, and endothelial cells. 4, 22 In vivo measures that attenuate the alloimmune response (immunosuppressives) 23 or inhibit arteriosclerotic lesion development in allografts 4, 24, 25 reduce NOS2 expression. However, the exact role of NOS2 in chronic cardiac rejection and development of transplant arteriosclerosis has yet to be defined.
The purpose of this study was to determine whether NOS2-mediated pathways promote or protect against transplant arteriosclerosis. Mice with targeted disruption of the NOS2 gene provide a valuable tool to study the functional role of NOS2 deficiency in the alloimmune response to MHC-mismatched grafts. NOS2 Ϫ/Ϫ knockout mice are viable, fertile, and without phenotypic evidence of histopathological abnormalities. 12, 26 However, when challenged, NOS2-deficient mice show altered immune responses to lipopolysaccharides and bacterial or parasitic infections. 12, 26 To study the role of NOS2 in arteriosclerosis initiated by an alloimmune injury, we used our vascularized heterotopic mouse cardiac transplantation model of attenuated rejection. 25 This T cell-dependent model permits evaluation of effector pathways that mediate the early immune and late myointimal stages of arteriosclerotic lesion development in response to alloimmune injury. To evaluate the effect of NOS2 on transplant arteriosclerosis, we compared frequency and severity of arteriosclerotic lesion development in grafts placed into NOS2-deficient and wild-type recipients. To study alterations in the early immune or late myointimal stages of transplant arteriosclerosis, we characterized T-cell differentiation and neointimal SMC accumulation.
Methods

Mice
Male CBA/CaJ (H-2 k ) mice 6 to 8 weeks old were used as heart donors. As organ recipients, male mice deficient in inducible NO synthase (NOS2 Ϫ/Ϫ) on a C57BL/6Jϫ129/Sv (H-2 b ) background 26 were compared with NOS2-competent wild-type mice. 
Heterotopic Cardiac Transplantation
Vascularized, heterotopic abdominal cardiac transplantation was performed as described by Corry et al. 27 Postoperatively, all recipients were prophylactically treated with trimethoprim/sulfamethoxazole (Bactrim, Roche Pharmaceuticals) in the drinking water (trimethoprim 80 mg/L, sulfamethoxazole 400 mg/L). Transplanted hearts were harvested as described previously. 25 Allografts from NOS2 Ϫ/Ϫ recipients (nϭ13) were compared with those from allogeneic wild-type recipients (B6 recipients, nϭ8; B6/129 recipients, nϭ7). Anti-CD4 and CD8 antibodies (GK1.5 and 2.43; 2.0 mg IP, days 1 to 4, and then weekly to day 28) were used as T-cell-depleting immunosuppressive therapy. This program of immunosuppression has been shown to produce cardiac allografts that undergo chronic rejection. 28 Native hearts from transplant recipients (NOS2 Ϫ/Ϫ and wild-type) exposed to the same circulation were used as one control group. Syngeneic isografts placed into untreated recipients (NOS2 Ϫ/Ϫ and wild-type) exposed to the same surgical procedure were used as a second control group. Graft function was monitored daily by measurement of the force of palpable heart beat. After perfusion with PBS, cardiac allografts were harvested at 55 days after transplantation.
Morphometric Analysis
Transverse heart sections were fixed in methyl Carnoy's solution and embedded in paraffin. Sections (4 m) were stained with Verhoeff's elastin for histological evaluation of cellular rejection and vascular analysis. Microscopic images of all elastin-positive vessels were captured. The captured images were used to trace the lumen, internal elastic lamina, and external elastic lamina (NIH 1.6 software). The intimal area was determined by subtracting the area of the lumen from the area enclosed by the internal elastic lamina. The medial area was determined by subtracting the area enclosed by the internal elastic lamina from the area enclosed by the external elastic lamina. From these data, we derived percent luminal occlusion 25 and intima/ media ratios. Values are calculated as the mean from all captured vessels per heart and reported as the meanϮSD for all grafts in each recipient group.
Immunohistological Analysis
As a marker of more advanced arteriosclerotic stages, 29 we estimated the contribution of SMCs to the expanded neointima. Immunohistochemical staining for ␣-SMC actin was compared in paraffin sections (4 m) from allografts transplanted into NOS2 Ϫ/Ϫ recipients (nϭ5) and B6 wild-type recipients (nϭ5). Duplicate sections were prestained with Verhoeff's elastin to detect the internal elastic lamina. ␣-SMC actin staining was performed as described previously 4 with a monoclonal mouse IgG2a antibody (1:20 000, overnight at 4°C) directed against ␣-actin (Sigma Chemical Co). Microscopic images of each vessel were captured separately. Differences in immunopositive cells were estimated by image analysis with NIH Image 1.6. For each vessel, the neointima was defined by tracing the internal elastic lamina and the lumen. The area stained specifically for ␣-SMC actin was detected by measurement of the area encompassed by pixels of the color intensity of immunopositive cells and tabulated as the percentage of the total neointimal area. A mean from all captured vessels per heart was calculated and is reported as mean value for all grafts in each recipient group. To localize NOS2 expression within the rejecting heart, immunohistochemical staining for NOS2 was compared in paraffin sections (4 m) from chronically rejecting allografts transplanted into NOS2 Ϫ/Ϫ and B6 wild-type recipients. Polyclonal rabbit anti-NOS2 was prepared by Jeffrey R. Weidner and Richard A. Mumford (Merck Research Laboratories) and kindly provided to us by Carl Nathan.
Selected Abbreviations and Acronyms
G -monomethyl-L-arginine NOS ϭ NO synthase NOS2 ϭ inducible NO synthase PCR ϭ polymerase chain reaction RT ϭ reverse transcription RU ϭ relative unit SMC ϭ smooth muscle cell STAT ϭ signal transducer and activator of transcription VSMC ϭ vascular smooth muscle cell Immunostaining was performed as described previously, 4 with a incubation time with polyclonal antiserum against NOS2 (1:250) of 60 minutes at room temperature. Negative controls included omission of primary or secondary antibody and staining of native heart sections from NOS2 Ϫ/Ϫ mice.
Reverse Transcriptase-Polymerase Chain Reaction
Semiquantitative 32 P RT-PCR to measure relative transcript levels was performed as described previously. 25 Briefly, total RNA was extracted from ventricular sections with RNAzol B (Tel-Test). First-strand cDNA synthesis using 2.5 g of total RNA per reaction was completed on all samples at the same time to ensure comparability between samples (cDNA kit, GIBCO BRL). Given the large number of grafts, the cDNA panel was restricted to the analysis of cDNA prepared from the following hearts: allografts placed in NOS2 Ϫ/Ϫ recipients (nϭ13) and B6 wild-type recipients (nϭ8) and native host hearts from NOS2 Ϫ/Ϫ (nϭ13) and B6 wild-type recipients (nϭ8). PCR primers designed by use of MacVector 5.0 (Oxford Molecular Scientific) were synthesized on an Oligo 1000 DNA Synthesizer (Beckman). Primer sequences, sequence accession numbers, annealing temperatures, and cycle numbers are listed in the Table. For each primer pair, conditions were optimized to generate a single specific band, and the identity was confirmed by restriction analysis. Triplicate samples were amplified with 0.625 U AmpliTaq Gold DNA polymerase (Perkin Elmer) in a total volume of 25 L. After initial activation of this specific polymerase at 95°C for 9 minutes, the thermal cycling parameters were denaturation at 94°C for 30 seconds, annealing at a primer-optimized temperature for 20 seconds, and extension at 72°C for 60 seconds (increased by 2 seconds per cycle), followed by a final extension of 7 minutes at the end of all cycles. [ 32 P]dCTP (150 000 cpm per reaction) was included for quantitative PCR studies. The amount of incorporated 32 P dCTP in amplified product bands from dried agarose gels was measured by volume integration (Molecular Dynamics). Corrected levels of the specific product were derived by dividing the amplified product value by the mean value of the control gene G3PDH in the respective sample. Corrected levels for T-cell transcription factors were standardized for CD4 (corrected level transcription factor /corrected level CD4 ).
Statistical Analysis
For comparison of two groups, an unpaired t test was used. A value of PϽ.05 was considered significant. For comparison of more than two groups, ANOVA was used. If the ANOVA was significant, the Bonferroni/Dunn procedure was used as a post hoc test. Group data are expressed as meanϮSD.
Results
Analysis of Transplant Arteriosclerosis
In this transplant model of attenuated rejection, all grafts transplanted in NOS2 Ϫ/Ϫ (nϭ13) or wild-type (total nϭ15) recipients survived to the end point of 55 days after transplantation. Native hearts and isografts had no significant vessel thickening. Allografts at 55 days from wild-type as well as NOS2 Ϫ/Ϫ recipients had typical circumferential thickening of the vessels with perivascular mononuclear cell infiltration. In diseased vessels, the internal elastic lamina was intact, with occasional breaks. The expanded neointima contained cells with features of mononuclear inflammatory cells and SMCs.
A total of 283 vessels (10.1Ϯ5.5 vessels per graft) were subjected to computer-assisted analysis to establish severity and frequency of arteriosclerotic lesion development (Fig 1) . The mean luminal area was significantly decreased in allografts from NOS2 Ϫ/Ϫ recipients (587Ϯ217 m 2 ) compared with those placed into both wild-type controls (B6, 1168Ϯ322 
NOS2 Expression in Cardiac Transplants
Corrected NOS2 transcript levels were evaluated by 32 P RT-PCR (Fig 2) . In wild-type recipients, the expected allograft-specific induction of NOS2 was confirmed by an increase in mean mRNA transcript levels in allografts (0.51Ϯ0.40 RU) compared with native hearts (0.17Ϯ0.19 RU, Pϭ.0014). However, there was a significant reduction in NOS2 transcript levels in allografts placed in NOS2 Ϫ/Ϫ recipients compared with grafts placed in wild-type recipients (PϽ.0001, Fig 2A) . NOS2 transcript levels were also increased in cardiac grafts placed in NOS2 Ϫ/Ϫ recipients (0.25Ϯ0.11 RU) compared with the paired native hearts (0.05Ϯ0.01 RU). This fivefold increase did not reach statistical significance with the present sample numbers of 13 allografts and 8 native hearts.
Immunostaining was performed to determine the cellular localization of NOS2. In allografts from wild-type recipients, both infiltrating recipient mononuclear cells and donor parenchymal cells (myocytes, SMCs, and endothelial cells) expressed NOS2 antigen (Fig 2B) , whereas in allografts from NOS2 Ϫ/Ϫ recipients, NOS2 antigen was absent in graftinfiltrating inflammatory cells and present only within donor parenchymal cells (myocytes, VSMCs, and endothelial cells; Fig 2C) . This coexistence of both donor and recipient sources of NOS2 in wild-type recipients underlines the chimeric nature of the myocardial microenvironment within the transplanted heart. In the setting of recipient NOS2 deficiency, there was attenuated NOS2 induction in allografts, with expression in the donor parenchyma but not graft-infiltrating recipient cells.
T-Cell Differentiation in Allografts From NOS2 ؊/؊ and Wild-type Recipients
Given that NO under some conditions is known to regulate Th 1 /Th 2 differentiation of CD4 ϩ lymphocytes, we used 32 P RT-PCR from graft tissue to compare the allograft-specific mRNA expression for the respective transcription factors and signature cytokines between the two recipient groups. As shown in Fig 3, there were no significant differences in the Th 1 response between grafts from either NOS2 Ϫ/Ϫ or wild- 
SMC Contribution to Neointimal Formation
To study whether NOS2 mediates its protective effects by attenuation of the later stage of myointimal expansion, we estimated the SMC contribution to the expanded neointima using ␣-SMC actin as a marker. Immunohistochemical staining for ␣-SMC actin was compared in a total of 66 vessels from 5 representative grafts each placed into NOS2 Ϫ/Ϫ and B6 wild-type recipients. Computer-assisted image analysis showed that grafts placed into NOS2 Ϫ/Ϫ recipients had a significant increase in the contribution of ␣-SMC actinpositive cell area within the expanded neointima (28.2Ϯ2.0%) compared with the neointimal area in control allografts (13.2Ϯ2.3%, PϽ.0001).
Discussion
Protracted alloimmune injury to the donor vasculature is believed to propagate the accelerated form of vascular thickening that accompanies chronic rejection. Here, we demonstrate that NOS2 plays a protective role in transplant arteriosclerosis by using NOS2 Ϫ/Ϫ mice as recipients in a heterotopic cardiac transplant model. We show that NOS2 deficiency results in significant increases in severity and frequency of intimal thickening in response to alloimmune injury. The medial areas were conserved among the groups. This indicates that the increased vessel occlusion resulted from increased intimal thickening as opposed to significant vessel shrinkage. Compared with previous studies using pharmacological NOS inhibitors, this experimental approach offers the advantage of ongoing and more specific NOS2 inhibition through targeted gene deletion. Hence, we establish that NOS2 has a causal role in the cascade that culminates in vascular remodeling in this alloimmunologically initiated form of arteriosclerosis.
NOS2 deficiency aggravated the degree of luminal occlusion in part by altering the SMC characteristics of the expanded neointima. Specifically, we show that the area of ␣-SMC actin-positive cells within the expanded neointima is significantly larger in grafts from NOS2-deficient recipients than wild-type recipients. Given that SMCs are characteristic of more advanced lesions, 29 this suggests that NOS2 interferes with the late stage of transplant arteriosclerosis by reducing neointimal SMC accumulation. This proarteriosclerotic effect seen in cardiac allografts from NOS2-deficient recipients might have arisen from changes in the temporal progression of this disease, the actual manner in which vascular remodeling occurs, or both.
NOS2 and VSMCs
There are a number of ways in which increased myointimal thickening might develop in this arteriosclerotic model. The SMC component of the neointima could increase from migration of VSMCs into the intima or proliferation of these immigrated cells. 30 Alternatively, there might also be decreased loss of intimal cells (ie, apoptosis), resulting in the accumulation of SMCs within the expanded intima. 31 In vitro evidence shows that endogenous NO can directly modulate VSMC migration as well as proliferation. First, addition of different NO donors reduced the number of migrating cultured VSMCs and the maximal distance migrated in a concentration-dependent manner. 13 Second, SMC migration resumed after removal of NO donors. Third, addition of NO donors also reduced serum-induced thymidine incorporation and significantly decreased proliferation of rat aortic SMCs. 14, 15 Conversely, there is evidence that NO can induce apoptosis. In vitro stimulation of rat VSMCs with IFN-␥ and tumor necrosis factor-␣ or IL-1␤ produced apoptotic cell death associated with increased elaboration of nitrite, an end product of NO. 31 Second, apoptosis is partially blocked by L-NMMA. Hence, at least in vitro, NO-dependent mechanisms can promote apoptosis in VSMCs.
In this and earlier studies, 4 we show that there is a differentiated or activated subset of SMCs within the media and neointima expressing NOS2. The presence of these differentiated sets of VSMCs expressing NO during more advanced stages of chronic cardiac rejection in this mouse and the LEW to F344 rat model 4 has suggested that vascular forms of NOS2 may serve a compensatory role to inhibit further arteriosclerotic thickening when the vessel reaches a quiescent stage. Our present results provide further support that one of the roles of NOS2 is probably to promote direct inhibitory actions of NO on VSMCs, as previously suggested by in vitro studies.
14
NOS2 and T-Cell Differentiation
One might also speculate that NO serves a role in regulating early immune system-mediated forces that lead to later myointimal expansion. The immune response to a specific stimulus has been hypothesized to involve the differentiation of CD4 ϩ T lymphocytes into Th 1 or Th 2 programs, 10,32 which differ in their cytokine secretion patterns and immunological effector functions. 10 NO could play a role by modulating the differentiation of T cells into distinct subsets of T helper cells (Th 1 and Th 2 ), altering the functions of these differentiated T cells, or both.
The expansion of Th 1 cells in NOS2-deficient mice after a strong microbial challenge shows that in some circumstances, NO can regulate T-cell differentiation. 12 In addition to regulating the differentiation of T cells, NO production itself is regulated by Th 1 -and Th 2 -type cytokines. For example, Th 1 -derived IL-2 and IFN-␥ alter macrophage effector functions by induction of NO, whereas Th 2 -derived IL-4 and IL-10 are able to inhibit the Th 1 -mediated induction of NOS. 33, 34 In vivo, it has been demonstrated that Th 1 -mediated protective immunity in a rodent malaria model involved NO-dependent mechanisms. 35 This was exemplified when L-NMMA reversed the protective effect on parasitemia seen in Th 1 -reconstituted mice.
We had hypothesized that an exaggerated Th 1 response produced by loss of NO-mediated inhibition of IL-2 and IFN-␥ would result in accelerated chronic rejection and transplant arteriosclerosis. The present results, demonstrating unchanged expression of the program-specific Th 1 and Th 2 transcription factors and intragraft cytokine levels, are inconsistent with this hypothesis. Instead, these findings suggest that exacerbation of transplant arteriosclerosis in NOS2-deficient recipients may arise as a CD4 ϩ -cell-independent process.
NOS2 and Arteriosclerosis
The present study is the first to use NOS2 knockout animals to demonstrate a protective, antiarteriosclerotic role for NO in an in vivo model of arteriosclerotic lesion development initiated by immune injury. Our findings confirm and extend studies showing reduced neointimal thickening after augmentation of NO production in various arteriosclerotic models. For example, administration of different NO donors [17] [18] [19] or gene transfer-mediated restoration of endothelial NOS 36 have been shown to suppress intimal thickening after carotid balloon injury. In a model of atherosclerotic lesion development in hypercholesterolemic rabbits, lesion development was attenuated by dietary supplementation of L-arginine, the precursor for NO. 37, 38 These antiarteriosclerotic effects could be blocked by coadministration of an inhibitor of NO synthases (N G -nitro-L-arginine methyl ester) in a rabbit model after balloon catheter-induced injury. 18 The fact that NOrelated antiarteriosclerotic effects are demonstrated in models based on an immune system-mediated injury (reported here) as well as in models of mechanically induced lesion development provides evidence for a immune cell-independent mode of action for NOS in arteriosclerotic syndromes.
NO is believed to maintain the integrity of coronary vessels through a wide range of physiological effects. 7 Hence, disrupted NO production has been hypothesized to promote various aspects of arteriosclerotic lesion development. NO could affect the leukocyte contribution to endothelial cell injury or vessel thickening in a number of ways. First, NO can inhibit leukocyte adhesion to the endothelium. 39 Impaired NO production in the vessel produces increased leukocyte adhesion and emigration. Thus, NO deficiency could promote the leukocyte-endothelium interaction that culminates in endothelial injury. Second, NO and its redox forms could control leukocyte accumulation within the expanded intima through apoptotic mechanisms. In vitro, the activity of NO synthase in macrophages has been shown to correlate inversely with their life span, 40 and this effect appears to be mediated through NO-triggered apoptosis. NO also modulates platelet-endothelium interactions. Ex vivo, NO inhibits platelet function by reducing ADP-induced platelet aggregation and effectively disaggregating already activated platelets. 41 This points to potential antithrombotic effects of NO in the preinjured endothelium. Besides its effects on VSMCs, endogenous NO has been demonstrated to effectively inhibit proliferation of fibroblasts. 42 In later stages of lesion development, NO could play an important role by mediating antiproliferative effects in different cell types that are considered essential components of late vascular remodeling.
Conclusions
The present study establishes that endogenous NOS2 participates in the antiarteriosclerotic response that regulates intimal thickening in chronically rejecting mouse cardiac allografts. The antiarteriosclerotic effect was independent of T-cell differentiation. Instead, the augmented intimal thickening in NOS2 Ϫ/Ϫ recipients correlated with an increased contribution of ␣-SMC actin-positive cells to the formation of the neointima. This suggests that NOS2 may mediate its protective effects by controlling neointimal SMC migration or proliferation. Ongoing exploration of the mechanisms through which NOS2 regulates vessel responses to alloim-mune injury in this mouse model may provide insight into its role in this and other forms of arteriosclerosis.
